Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Viridian Therapeutics, Inc.

VRDN

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Viridian Therapeutics, Inc.. A complete text table follows the diagram.

Viridian thyroid-eye platform

Clinical-stage antibodies target thyroid eye disease and other immune-mediated conditions.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001590750-26-000012
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

Values are in millions of USD unless otherwise noted.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Total reported revenue	1	$116M	Reported filing total
Immune-medicine platform	2	$116M	Company-specific editorial view

Financial flows · Millions of USD
From	To	Value
Total reported revenue	Immune-medicine platform	$116M